Contact
Please use this form to send email to PR contact of this press release:
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510), decision type: , therapeutic area: , PIP number: P/0261/2022
TO: